05.04.2010: Selecta Biosciences announces the closing of a $15M Series C financing to expand development of a new class of vaccines based on Selecta's targeted Synthetic Vaccine Particle (SVP) platform. The investment was led by OrbiMed Advisors, with participation by all existing investors, Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments.

Press Release

Editorial in FierceBiotech (April 5, 2010)